



The 65th ASH Annual Meeting Abstracts

POSTER ABSTRACTS

651. MULTIPLE MYELOMA AND PLASMA CELL DYSCRASIAS: BASIC AND TRANSLATIONAL

The Spop/BRD4/c-Myc Axis Modulates IMiDs Sensitivity in Multiple MyelomaLijie Xing, MD¹, Jiye Liu, PhD², Kenneth Wen, BS², Teru Hideshima², Kenneth C. Anderson, MD³, Zengjun Li⁴¹ Department of Lymphoma and Hematology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Brookline, MA² Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA³ Dana-Farber Cancer Institute, Harvard Medical School, The Jerome Lipper Multiple Myeloma Center, Boston, MA⁴ Department of Lymphoma and Hematology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Ji'nan, China

The development of novel agents including immunomodulatory drugs (IMiDs) lenalidomide (Len) and pomalidomide (Pom) has led to improved patient outcomes in multiple myeloma (MM); however, MM patients inevitably experience relapse and drug resistance. The expression level of CRBN, CRBN-binding proteins, and CRL4^{CRBN} ubiquitin ligase is considered to be associated with IMiDs resistance. Clinical studies have shown that MM patients can exhibit IMiDs resistance even without CRBN abnormalities, suggesting the molecular mechanisms of intrinsic resistance to IMiDs are not fully understood.

To delineate the molecular mechanisms underlying IMiDs resistance, we performed genome-wide knockout (KO) screening in IMiDs-sensitive MM cells. For *in vitro* work, we used the MM cell lines MM1S, and H929. We used sgRNA to KO *SPOP* and *BRD4* in MM cells.

After performing a CRISPR KO screen in MM cells, we discovered that in addition to CRBN and its associated genes, sgRNAs targeting *SPOP* (speckle-type POZ protein, a speckled zinc finger protein) were highly enriched after treatment with Poma. Importantly, *SPOP* KO MM cell lines acquired significant resistance to Pom and Len treatment. To examine whether *SPOP* KO-induced IMiDs resistance was CRBN-pathway dependent, we assessed CRBN and its downstream interacting protein levels. *SPOP* KO showed no effect on CRBN expression; moreover, IMiDs can still trigger IKZF1 and IKZF3 degradation, associated with the downregulation of IRF4, suggesting that *SPOP* mediates sensitivity to IMiDs in a mechanism independent of CRBN-IKZF1/3 axis. Compared to plasma cells from normal donors, we found that the expression levels of *SPOP* were significantly decreased in MGUS patients, smoldering myeloma patients, newly diagnosed MM patients, and refractory relapsed MM patients (p-values: 2.4e-2, 2.0e-4, 9.9e-3, 3.17e-6, respectively).

SPOP is the adaptor protein of the Cullin3-RING ubiquitin ligase complex. Therefore, the function of *SPOP* is determined by the characteristics of the substrates it recruits. We performed immunoprecipitation with overexpressed *SPOP* in MM cells, followed by mass spectrometry analysis, and identified *BRD4* as a candidate protein binding to *SPOP* in MM, which was confirmed by Co-IP. KO of *SPOP* led to an upregulation of *BRD4* protein levels in MM cells. As a downstream regulator of *BRD4*, the oncogene *c-Myc* showed a significant increase in protein expression in IMiDs-resistant MM patients. Furthermore, the KO of *SPOP* notably enhanced *c-Myc* expression in MM cells, while the KO of *BRD4* in *SPOP* KO MM cells decreased *c-Myc* expression and restored MM cell sensitivity to IMiD treatment. These findings suggest that *SPOP* modulates *c-Myc* expression through *BRD4* in a CRBN-IKZF1/3 independent manner, thereby mediating MM cell sensitivity to IMiDs.

BRD4 plays a significant role in the development and progression of various tumors. The *BRD4* inhibitor JQ1 has been shown to exhibit anti-tumor effects in multiple types of cancer. We found that combination treatment with JQ-1 and IMiDs reversed IMiDs resistance of *SPOP* KO MM cell lines and primary MM cells from relapsed patients.

Our data show that *SPOP* is a CRBN-independent modulator of IMiDs sensitivity by regulating the *BRD4/c-Myc* axis and provides the preclinical rationale for combining IMiDs with *BRD4* inhibitors to overcome IMiDs resistance and improve patient outcomes.

Disclosures Anderson: C4 Therapeutics, Raqia, NextRNA, Dynamic Cell Therapy: Current equity holder in publicly-traded company, Current holder of stock options in a privately-held company, Membership on an entity's Board of Directors or advisory committees; Oncopep: Current equity holder in private company, Current holder of stock options in a privately-held company; NextRNA: Current equity holder in private company; Dynamic Cell Therapies: Current equity holder in private

company, Current holder of stock options in a privately-held company, Membership on an entity's Board of Directors or advisory committees; Pfizer, Janssen, Astrazeneca, Daewoong, Amgen, Starton, OncoPep, Precision Biosciences, Window Therapeutics, Mana Therapeutics: Membership on an entity's Board of Directors or advisory committees; Window, Starton: Current equity holder in private company, Current holder of stock options in a privately-held company, Membership on an entity's Board of Directors or advisory committees.




Figure 1: This schematic illustrates the role of SPOP in inducing IMiDs resistance through the BRD4/c-Myc axis in multiple myeloma (MM) and proposes potential strategies to overcome this resistance.

Figure 1

<https://doi.org/10.1182/blood-2023-187762>

Downloaded from http://ashpublications.net/blood/article-pdf/142/Supplement_1/4687/2192419/blood-1288-main.pdf by guest on 18 May 2024